EUCTR2022-000753-80-DK进行中（未招募）1 期
A randomised, assessor-blind, active-controlled, parallel-group, dose-finding trial to investigate the efficacy and safety of FE 999302 for triggering of final follicular maturation in women undergoing controlled ovarian stimulation - TIFFANY
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Subject informed consent form signed prior to any trial-related activities.
- •2. Parental informed consent form signed prior to start of stimulation in the trial.
- •3. In good physical and mental health as judged by the investigator.
- •4. Pre-menopausal women between the ages of 18 and 42 years. The subjects must be at least 18 years (including the 18th birthday) and no more than 42 years (up to the day before the 43rd birthday) when they sign the informed consent.
- •5. Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II or with partners diagnosed with male factor infertility, eligible for in vitro fertilisation (IVF) and/or intracytoplasmic sperm injection (ICSI) using fresh or frozen ejaculated sperm from male partner or sperm donor.
- •6. Infertility for at least 1 year before screening for subjects <35 years or for at least 6 months for subjects =35 years (not applicable in case of tubal or severe male factor infertility).
- •7 No more than two controlled ovarian stimulation cycles initiated, regardless outcome (taking exclusion criteria 3, 4, and 5 into account).
- •8. Regular menstrual cycles of 24-35 days (both inclusive), presumed to be ovulatory.
- •9. Hysterosalpingography, hysteroscopy, saline infusion sonography, or transvaginal ultrasound documenting a uterus consistent with expected normal function (e.g. no evidence of clinically interfering uterine fibroids defined as submucous or intramural fibroids larger than 3 cm in diameter, no polyps, and no congenital structural abnormalities which are associated with a reduced chance of pregnancy) within 1 year prior to start of stimulation in the trial.
- •10. Transvaginal ultrasound documenting presence and adequate visualisation of both ovaries, without evidence of significant abnormality (e.g. enlarged ovaries which would contraindicate the use of gonadotropins) and normal adnexa (e.g. no hydrosalpinx) within 1 year prior to start of stimulation in the trial. Both ovaries must be accessible for oocyte retrieval.
- •11. Early follicular phase (cycle day 2-4) serum levels of follicle-stimulating hormone (FSH) between 1 and 15 IU/L (results obtained within 3 months prior to start of stimulation in the trial).
- •12. Negative serum Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) antibody tests within 1 year prior to start of stimulation in the trial.
- •13. Follicular development with =3 follicles with a diameter =17 mm and <20 follicles with a diameter =12 mm observed on transvaginal ultrasound at the end of stimulation in the trial cycle.
- •14. Willing to accept ICSI regardless the cause of infertility.
- •15. Willing to accept transfer of a single good-quality blastocyst (double blastocyst transfer is allowed if no good-quality blastocyst is available).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 500
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Known polycystic ovary syndrome (PCOS) associated with anovulation or known endometriosis stage III-IV
- •2. Considered unsuitable for controlled ovarian stimulation with a starting dose of 150 or 225 IU/day highly purified human menopausal gonadotropin (HP-hMG), as judged by the investigator.
- •3. Poor response in a previous controlled ovarian stimulation cycle using a gonadotropin starting dose of 150 IU/day or higher. Poor response is defined as <4 oocytes retrieved, or cycle cancellation prior to oocyte retrieval due to inadequate follicular development.
- •4. Excessive ovarian response in a previous controlled ovarian stimulation cycle for IVF/ICSI using a daily FSH/hMG dose of <225 IU, defined as =25 oocytes retrieved or cycle cancellation prior to oocyte retrieval due to excessive ovarian response, including risk of ovarian hyperstimulation syndrome (OHSS).
- •5. Severe OHSS in a previous controlled ovarian stimulation cycle.
- •6. One or more follicles =10 mm (including cysts) observed on the transvaginal ultrasound prior to start of ovarian stimulation on stimulation day 1 (puncture of cysts is allowed prior to start of stimulation).
- •7. Known history of recurrent miscarriage (defined as three consecutive losses after ultrasound confirmation of pregnancy and before week 24 of pregnancy, excluding ectopic pregnancy).
- •8. Known abnormal karyotype of subject or of her partner/sperm donor, as applicable, depending on source of sperm used for insemination in this trial. In case partner sperm will be used and the sperm production is severely impaired (concentration <1 million/mL), normal karyotype, including no Y-chromosome microdeletion, must be documented.
- •9. Any known clinically significant systemic disease (e.g. insulin-dependent diabetes).
- •10. Known inherited or acquired thrombophilia disease.
- •11. Known active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.
- •12. Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver, or kidney) with the exception of controlled thyroid function disease.
- •13. Known presence of anti-hCG antibodies (based on the information available in the subject’s medical records; i.e. not based on the anti-hCG antibody analyses conducted in the trial).
- •14. Known tumours of the ovary, breast, uterus, adrenal gland, pituitary, or hypothalamus which would contraindicate the use of gonadotropins.
- •15. Known impairment of renal or hepatic function.
- •16. Any abnormal finding of clinical chemistry and haematology at screening or vital signs at randomisation, which is judged clinically relevant by the investigator and/or requires intervention.
- •17. Currently breast-feeding.
- •18. Undiagnosed vaginal bleeding.
- •19. Known abnormal cervical cytology of clinical significance observed within 3 years prior to start of stimulation in the trial (unless the clinical significance has been resolved).
- •20. Findings at the gynaecological examination at screening which preclude gonadotropin stimulation or are associated with a reduced chance of pregnancy, e.g. congenital uterine abnormalities or retained intrauterine device.
- •21. Pregnancy (negative urinary pregnancy tests must be documented at screening and prior to start of stimulation) or contraindication to pregnancy.
- •22. Known current active pelvic inflammatory disease.
- •23. Use of fertility modifiers during the last menstrual cycle before start of stimulation in the trial, including dehydroepiandrosterone (DHEA) or cycle progra
研究者
相似试验
进行中（未招募）
1 期
To find the effectiveness of a new allogenic cell-based wound dressing (VELGRAFT) in the treatment of chronic diabetic foot ulcer that have attained granulation. A phase 1 trial.CTRI/2023/03/050855Datt Mediproducts Private Limited
招募中
2 期
Clinical study for the treatment of white patches (vitiligo) with unani and allopathic medicineCTRI/2020/09/028107ational Research Institute of Unani medicine for Skin disorders
尚未招募
2 期
A comparative Clinical Study to evaluate the safety and efficacy of a unani formulation in the Management of Wajaâ??al-MafÄ?á¹£il (Rheumatoid Arthritis)CTRI/2020/03/024187ational Research Institute of Unani Medicine for Skin Disorders Hyderabad
已完成
1 期
This is trial that has an objective of evaluating the local and systemic safety and tolerability of the new steroid, that is administered as a nasal spray, in healthy male volunteers.CTRI/2011/03/001651Atul Raut MD PhD40
进行中（未招募）
1 期
Effect on secukinumab on radiographic progression in ankylosing spondylitis as compared to GP2017 (adalimumab biosimilar)Ankylosing spondylitisMedDRA version: 20.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2017-000679-10-ESovartis Farmacéutica, S.A.837